Bayer inks licensing deal with Cedilla to boost oncology pipeline

• German conglomerate Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) has entered into an exclusive licensing arrangement to advance early-stage cancer drugs being developed by U.S.-based Cedilla Therapeutics, the companies announced Thursday.
• The preclinical compounds known as CyclinE1/CDK2 complex inhibitors are designed to target certain oncogenic processes found in several cancers.
• “We are excited to bring these highly innovative preclinical programs in-house that complement our early pipeline in precision oncology,” remarked Dominik Ruettinger, Bayer’s (OTCPK:BAYZF) global head of R&D for oncology drugs.
• Per the terms, Bayer will own full rights to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors in exchange for an upfront payment, milestone payments, and royalties. Financial terms of the transaction were not disclosed.

More on Bayer

• Bayer's kidney disease drug Kerendia gets Chinese regulator nod for expanded use
• Bayer Agriscience, Shades Of Corteva